Insights

Innovative Tech Focus VeriSIM Life specializes in AI-enabled biosimulation models aimed at revolutionizing drug development processes. Their technology offers significant efficiency improvements by modeling drug interactions virtually, presenting a compelling solution for pharmaceutical companies seeking to reduce reliance on animal testing and accelerate pipeline progression.

Awards and Recognition The company has received prestigious industry awards such as the Machine Learning Platform of the Year and recognition in Women in AI, highlighting its leadership in AI-driven drug discovery. These accolades position VeriSIM as a credible partner for forward-thinking pharma organizations seeking innovative collaborations.

Funding and Growth Potential With $15 million in funding and a lean team of 11-50 employees, VeriSIM is positioned for targeted growth. This funding indicates active investor confidence, which can be leveraged to explore strategic partnerships or pilot programs with larger biotech firms.

Market Opportunity The company's solution addresses a critical bottleneck in drug development, offering to drastically increase candidate testing throughput. This presents an opportunity to partner with mid-sized and large pharma companies looking to improve success rates and reduce time-to-market for new drugs.

Leadership and Credibility Led by CEO Dr. Jo Varshney, who has earned industry awards and recognition, VeriSIM benefits from strong leadership credibility. Connecting with companies that value innovative leadership and women-led ventures could open doors for strategic engagement and collaboration.

VeriSIM Life Tech Stack

VeriSIM Life uses 8 technology products and services including Hotjar, AdRoll CMP System, Open Graph, and more. Explore VeriSIM Life's tech stack below.

  • Hotjar
    Analytics
  • AdRoll CMP System
    Consent Management
  • Open Graph
    Content Management System
  • Google Sheets
    Office Suites
  • Webflow
    Page Builders
  • reCAPTCHA
    Security
  • HSTS
    Security
  • Facebook
    Widgets

Media & News

VeriSIM Life's Email Address Formats

VeriSIM Life uses at least 1 format(s):
VeriSIM Life Email FormatsExamplePercentage
First.Last@verisimlife.comJohn.Doe@verisimlife.com
49%
FiLast@verisimlife.comJoDoe@verisimlife.com
1%
First.Last@verisimlife.comJohn.Doe@verisimlife.com
49%
FiLast@verisimlife.comJoDoe@verisimlife.com
1%

Frequently Asked Questions

Where is VeriSIM Life's headquarters located?

Minus sign iconPlus sign icon
VeriSIM Life's main headquarters is located at 505 Montgomery St, San Francisco, California, US. The company has employees across 2 continents, including North AmericaEurope.

What is VeriSIM Life's official website and social media links?

Minus sign iconPlus sign icon
VeriSIM Life's official website is verisimlife.com and has social profiles on LinkedInCrunchbase.

What is VeriSIM Life's SIC code NAICS code?

Minus sign iconPlus sign icon
VeriSIM Life's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does VeriSIM Life have currently?

Minus sign iconPlus sign icon
As of October 2025, VeriSIM Life has approximately 20 employees across 2 continents, including North AmericaEurope. Key team members include Head Of Biosimulations: D. B.Executive Assistant To Ceo: B. W.Senior Computational Chemist: A. T.. Explore VeriSIM Life's employee directory with LeadIQ.

What industry does VeriSIM Life belong to?

Minus sign iconPlus sign icon
VeriSIM Life operates in the Biotechnology Research industry.

What technology does VeriSIM Life use?

Minus sign iconPlus sign icon
VeriSIM Life's tech stack includes HotjarAdRoll CMP SystemOpen GraphGoogle SheetsWebflowreCAPTCHAHSTSFacebook.

What is VeriSIM Life's email format?

Minus sign iconPlus sign icon
VeriSIM Life's email format typically follows the pattern of First.Last@verisimlife.com. Find more VeriSIM Life email formats with LeadIQ.

How much funding has VeriSIM Life raised to date?

Minus sign iconPlus sign icon
As of October 2025, VeriSIM Life has raised $15M in funding. The last funding round occurred on Jan 13, 2022 for $15M.

When was VeriSIM Life founded?

Minus sign iconPlus sign icon
VeriSIM Life was founded in 2017.
VeriSIM Life

VeriSIM Life

Biotechnology ResearchUnited States11-50 Employees

VeriSIM Life is building AI enabled biosimulation models. 
VeriSIM will tackle one of the biggest obstacles of drug development: animal testing for drug development. Animal testing is slow, ethically questionable, and doesn't act as much of a filter: 92% of all drug candidates that pass this preclinical testing never make it to market. 

VeriSIM's solution is to create disease-specific biosimulation models, which allow researchers at pharma companies to model in software how a drug will interact in animals. This will allow researchers to test 1000x more potential candidates in the same unit of time, ensuring that drugs that do make it to (human) clinical trials are far more likely to work, and therefore saving millions in annual costs.

Section iconCompany Overview

Headquarters
505 Montgomery St, San Francisco, California, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $15M

    VeriSIM Life has raised a total of $15M of funding over 4 rounds. Their latest funding round was raised on Jan 13, 2022 in the amount of $15M.

  • $1M$10M

    VeriSIM Life's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $15M

    VeriSIM Life has raised a total of $15M of funding over 4 rounds. Their latest funding round was raised on Jan 13, 2022 in the amount of $15M.

  • $1M$10M

    VeriSIM Life's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.